Glaxosmithkline plc (GSK) pledged $2.1 billion up front and as much as $1.2 billion in development milestone payments to take over privately held Affinivax Inc. and bring aboard the phase II-stage, next-generation, 24-valent pneumococcal vaccine candidate, AFX-3772。总部位于伦敦的GSK在今年第三季度完成交易后,以21亿美元的价格购买了马萨诸塞州剑桥市的Affinivax的所有流通股,如果某些儿科发展目标是某些儿科发展目标,则支付两项潜在的里程碑式支付6亿美元到达。